Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Follow-up studies of eating disorders (EDs) suggest outcomes ranging from recovery to chronic illness or death, but predictors of outcome have not been consistently identified. We tested 5151 single-nucleotide polymorphisms (SNPs) in approximately 350 candidate genes for association with recovery from ED in 1878 women. Initial analyses focused on a strictly defined discovery cohort of women who were over age 25 years, carried a lifetime diagnosis of an ED, and for whom data were available regarding the presence (n = 361 ongoing symptoms in the past year, ie, 'ill') or absence (n = 115 no symptoms in the past year, ie, 'recovered') of ED symptoms. An intronic SNP (rs17536211) in GABRG1 showed the strongest statistical evidence of association (p = 4.63 x 10(-6), false discovery rate (FDR) = 0.021, odds ratio (OR) = 0.46). We replicated these findings in a more liberally defined cohort of women age 25 years or younger (n = 464 ill, n = 107 recovered; p = 0.0336, OR = 0.68; combined sample p = 4.57 x 10(-6), FDR = 0.0049, OR = 0.55). Enrichment analyses revealed that GABA (gamma-aminobutyric acid) SNPs were over-represented among SNPs associated at po0.05 in both the discovery (Z = 3.64, p = 0.0003) and combined cohorts (Z = 2.07, p = 0.0388). In follow-up phenomic association analyses with a third independent cohort (n = 154 ED cases, n = 677 controls), rs17536211 was associated with trait anxiety (p = 0.049), suggesting a possible mechanism through which this variant may influence ED outcome. These findings could provide new insights into the development of more effective interventions for the most treatment-resistant patients. Neuropsychopharmacology (2011) 36, 2222-2232; doi: 10.1038/npp. 2011.108; published online 13 July 2011